{"id":305069,"date":"2026-08-21T00:00:00","date_gmt":"2026-08-21T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2024-biopharma-colorectal-cancer-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-09-04T23:21:31","modified_gmt":"2026-09-04T23:21:31","slug":"dlsfon0002-2026-biopharma-colorectal-cancer-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2026-biopharma-colorectal-cancer-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Colorectal Cancer &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Doublet or triplet chemotherapy, alone or in combination with angiogenesis inhibitors, remains the cornerstone of treatment for metastatic colorectal cancer. Patients without <i><abbr data-abbreviation-entity=\"6567\" title=\"rat sarcoma\">RAS<\/abbr><\/i> or <em><abbr data-abbreviation-entity=\"8174\" title=\"B-Raf proto-oncogene, serine\/threonine kinase\">BRAF<\/abbr> <\/em>mutations also benefit from <abbr data-abbreviation-entity=\"5565\" title=\"epidermal growth factor receptor\">EGFR<\/abbr> inhibitors (Merck &#038; Co. \/ Eli Lilly\u2019s Erbitux and Amgen\u2019s Vectibix), which are recommended for first-line treatment of patients with left-sided tumors. Additional targeted therapies have expanded treatment options for specific molecular subgroups, including immune checkpoint inhibitors (Merck &#038; Co.\u2019s Keytruda and Bristol Myers Squibb\u2019s Opdivo and Yervoy) for <abbr data-abbreviation-entity=\"5647\" title=\"microsatellite instability\">MSI<\/abbr>-high and\/or <abbr data-abbreviation-entity=\"10025\" title=\"DNA mismatch repair-deficient\">dMMR<\/abbr> tumors, <abbr data-abbreviation-entity=\"8174\" title=\"B-Raf proto-oncogene, serine\/threonine kinase\">BRAF<\/abbr> inhibitors (Array BioPharma \/ Pfizer\u2019s Braftovi) for <i><abbr data-abbreviation-entity=\"8174\" title=\"B-Raf proto-oncogene, serine\/threonine kinase\">BRAF<\/abbr> V600E<\/i>-mutated disease, <abbr data-abbreviation-entity=\"5343\" title=\"Kirsten rat sarcoma viral oncogene homolog\">KRAS<\/abbr> G12C inhibitors (Bristol Myers Squibb\u2019s Krazati and Amgen\u00b4s Lumakras) for <i><abbr data-abbreviation-entity=\"5343\" title=\"Kirsten rat sarcoma viral oncogene homolog\">KRAS<\/abbr> G12C<\/i>-mutated tumors, and <abbr data-abbreviation-entity=\"4839\" title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-targeting agents\u00a0(Chugai\u2019s Perjeta and trastuzumab and Seagen\u2019s Tukysa), available in some markets for <abbr data-abbreviation-entity=\"4839\" title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-positive metastatic disease.<\/p>\n<p>Late-phase development programs will further broaden the treatment landscape both in early-stage and metastatic colorectal cancer. In early-stage colon and rectal cancers, immune checkpoint inhibitors aim to expand the role of immunotherapy beyond the metastatic setting for <abbr data-abbreviation-entity=\"5647\" title=\"microsatellite instability\">MSI<\/abbr>-high\/<abbr data-abbreviation-entity=\"10025\" title=\"DNA mismatch repair-deficient\">dMMR<\/abbr> tumors. In metastatic disease, key areas of investigation include therapies targeting <abbr data-abbreviation-entity=\"10180\" title=\"mesenchymal epithelial transition factor\">MET<\/abbr> and <abbr data-abbreviation-entity=\"11029\" title=\"carcinoembryonic antigen-related cell adhesion molecule 5\">CEACAM5<\/abbr> expression, next-generation <abbr data-abbreviation-entity=\"5343\" title=\"Kirsten rat sarcoma viral oncogene homolog\">KRAS<\/abbr> G12C inhibitors for <em><abbr data-abbreviation-entity=\"5343\" title=\"Kirsten rat sarcoma viral oncogene homolog\">KRAS<\/abbr> G12C<\/em>-mutated tumors, novel <abbr data-abbreviation-entity=\"5565\" title=\"epidermal growth factor receptor\">EGFR<\/abbr>-directed therapies for <abbr data-abbreviation-entity=\"6567\" title=\"rat sarcoma\">RAS<\/abbr>\/<abbr data-abbreviation-entity=\"8174\" title=\"B-Raf proto-oncogene, serine\/threonine kinase\">BRAF<\/abbr> wild-type disease, and immunotherapy-based approaches for <abbr data-abbreviation-entity=\"7110\" title=\"microsatellite stable \">MSS<\/abbr>\/<abbr data-abbreviation-entity=\"10118\" title=\"DNA mismatch repair-proficient\">pMMR<\/abbr> disease.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers?<\/li>\n<li>What is the current treatment landscape in colorectal cancer? Which currently approved drugs are the most prescribed and why?<\/li>\n<li>Which are the most promising agents in the pipeline, and how will they shape the future of the colorectal cancer therapy market?<\/li>\n<li>What are the key drivers and constraints in the colorectal cancer therapy market, and how will they evolve over the forecast period? <\/li>\n<\/ul>\n<p><strong>Geography: <\/strong>United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p><strong>Primary research: <\/strong>Country-specific interviews with thought-leading medical oncologists; survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed and recurrent incidence of colorectal cancer; drug-treatable and -treated cases by country, disease stage, tumor side, <abbr data-abbreviation-entity=\"5338\" title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolog B1\">BRAF<\/abbr> status, and <abbr data-abbreviation-entity=\"6567\" title=\"rat sarcoma\">RAS<\/abbr> status<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key colorectal cancer therapies through 2035, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-305069","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-colorectal-cancer","biopharma-therapy-areas-solid-tumors","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=305069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}